Charles River Laboratories Announces Second-Quarter 2025 Results

Did the release mention any impacts from recent regulatory or political developments that could affect the business? How did the profit margins compare to prior quarters and to peers in the life‑science services sector? How is the company's cash flow and balance‑sheet strength positioned for potential reinvestment or capital returns? How might this earnings result affect the stock’s short‑term trajectory and trading volume? What is the outlook for pricing pressure or cost inflation in the company's operating environment? What trends emerged in each business segment (e.g., drug development, safety assessment, regulatory services) and how might they affect future growth? Are there any notable changes in the customer pipeline, such as new large contracts or lost contracts? Did the company provide any revised guidance for FY2025 or FY2026? Did the management comment on any strategic initiatives (e.g., acquisitions, R&D investments, partnership expansions) that could influence long‑term performance? What were the actual revenue and earnings figures versus analysts' expectations?